Literature DB >> 16492578

Developments in pharmacotherapy for tobacco dependence: past, present and future.

Jonathan Foulds1, Michael B Steinberg, Jill M Williams, Douglas M Ziedonis.   

Abstract

In the mid-1970s there were no effective pharmacological treatments for tobacco dependence. The invention of nicotine gum was a major treatment advance and also greatly helped our understanding of the nature of tobacco dependence. There are now eight effective pharmacotherapies (nicotine gum, patch, nasal spray, inhaler, lozenge/tablet, bupropion, nortriptyline and clonidine) available to aid smoking cessation. Other non-nicotine agents that show promise are under investigation, including glucose, rimonabant, selegiline and varenicline. Greater knowledge of the mechanisms of action of the effective non-nicotine agents should lead to better understanding of the nature of tobacco dependence. Future research into optimal treatments should examine long-term combination pharmacotherapy combined with improved psychosocial support that is partly designed to enhance medication compliance. In addition, there is a need for studies designed to evaluate the efficacy of pharmacotherapies in populations such as youth, pregnant smokers and smokers with co-occurring mental health problems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16492578     DOI: 10.1080/09595230500459529

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  21 in total

1.  Exploring scenarios to dramatically reduce smoking prevalence: a simulation model of the three-part cessation process.

Authors:  David T Levy; Patricia L Mabry; Amanda L Graham; C Tracy Orleans; David B Abrams
Journal:  Am J Public Health       Date:  2010-05-13       Impact factor: 9.308

2.  Evaluating the Effects of Varenicline on Craving, Withdrawal, and Affect in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline for Smokeless Tobacco Dependence in India.

Authors:  Sonali Jhanjee; Raka Jain; Veena Jain; Tina Gupta; Swati Mittal; Patricia Goelz; Robert A Schnoll
Journal:  J Psychoactive Drugs       Date:  2015-08-28

3.  An online survey of tobacco use, intentions to quit, and cessation strategies among people living with bipolar disorder.

Authors:  Judith J Prochaska; Reason S Reyes; Steven A Schroeder; Allen S Daniels; Allen Doederlein; Brenda Bergeson
Journal:  Bipolar Disord       Date:  2011 Aug-Sep       Impact factor: 6.744

4.  Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.

Authors:  Rebecca L Ashare; Sherry A McKee
Journal:  Exp Clin Psychopharmacol       Date:  2011-09-26       Impact factor: 3.157

Review 5.  Varenicline: a review of its use as an aid to smoking cessation therapy.

Authors:  Gillian M Keating; M Asif A Siddiqui
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation.

Authors:  Kenneth A Perkins; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2013-12-03       Impact factor: 4.530

7.  Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications.

Authors:  Kenneth A Perkins; Caryn Lerman; Joshua L Karelitz; Nancy C Jao; K N Roy Chengappa; Garrett M Sparks
Journal:  Addiction       Date:  2013-07-12       Impact factor: 6.526

8.  Snus use and other correlates of smoking cessation in the Swedish Twin Registry.

Authors:  H Furberg; P Lichtenstein; N L Pedersen; C M Bulik; C Lerman; P F Sullivan
Journal:  Psychol Med       Date:  2008-09       Impact factor: 7.723

9.  Partial nicotinic acetylcholine (alpha4beta2) agonists as promising new medications for smoking cessation.

Authors:  J Singh; Salil Budhiraja
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

Review 10.  Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century.

Authors:  Rafael Laniado-Laborín
Journal:  Int J Environ Res Public Health       Date:  2009-01-09       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.